The European Medicines Agency’s (EMA) safety committee concluded on Friday 11 June that people who have already experienced capillary leak syndrome should not receive the vaccine developed by AstraZeneca.
This syndrome, the EMA recalls, is a very rare and serious condition that causes fluid leakage from small blood vessels, resulting in, among other things, “low blood pressure, thickening of the blood and low blood levels of albumin (an important blood protein)”.
The EMA has...